_OMeCTP | 143028-98-2

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘧啶核苷酸
• 英文名称: _OMeCTP
• 英文别名: 2'-O-Methylcytidine 5'-triphosphate；2'-O-methyl-cytidine triphosphate；2'-O-methyl-CTP；2'-OMe-CTP；2'-OCH3-CTP；[[(2R,3R,4R,5R)-5-(4-amino-2-oxo-pyrimidin-1-yl)-3-hydroxy-4-methoxy-tetrahydrofuran-2-yl]methoxy-hydroxy-phosphoryl] phosphono hydrogen phosphate；[[(2R,3R,4R,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-3-hydroxy-4-methoxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate
• CAS: 143028-98-2
• 化学式: C₁₀H₁₈N₃O₁₄P₃
• 分子量: 497.186
• InChiKey: YCZSHICNESTART-ZOQUXTDFSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -5.1
• 重原子数：
  30
• 可旋转键数：
  9
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  257
• 氢给体数：
  6
• 氢受体数：
  14

反应信息

• 作为产物：
  描述：

  5'-O-(4,4'-dimethoxytrityl)-N⁴-isobutyryl-2'-O-methylcytidine 生成 _OMeCTP
  参考文献：
  名称：

  Novel solid phase synthesis of 2'-o-methylribonucleoside 5'-triphosphates and their α-thio analogues

  摘要：

  Simple, versatile and convenient syntheses of 2'-0-methyl-ribonucleoside 5'-triphosphates have been accomplished on controlled pore glass (CPG) in good yield (>60%) using 2-chloro-4H-1,3,2-benzodioxaphosphorin-4-one (salicyl phosphorochloridite). Moderate yields were obtained for the corresponding alpha-thiotri-phosphates.

  DOI：

  10.1016/s0040-4039(00)92072-0

文献信息

• POLY(PHOSPHOESTERS) FOR DELIVERY OF NUCLEIC ACIDS
  申请人：TRANSLATE BIO, INC.

  公开号：US20200277446A1

  公开（公告）日：2020-09-03

  Disclosed are polymers comprising the moiety A, which is a moiety of formula I: and pharmaceutically acceptable salts thereof, wherein R, R 1 , R 2 , L, n1 and n2 are as defined herein. These polymers are useful for delivering nucleic acids to subject. These polymers and pharmaceutically acceptable compositions comprising such polymers and nucleic acids can be useful for treating various diseases, disorders and conditions.

  揭示了包含A基团的聚合物，该基团是化学式I的基团：及其药用可接受的盐，其中R、R1、R2、L、n1和n2如本文所定义。这些聚合物对于将核酸传递给受试者是有用的。这些聚合物和包含这些聚合物和核酸的药用可接受组合物可用于治疗各种疾病、疾病和症状。
• Biodegradable lipids for delivery of nucleic acids
  申请人：TRANSLATE BIO, INC.

  公开号：US10022455B2

  公开（公告）日：2018-07-17

  The present invention provides, in part, a biodegradable compound of formula I, and sub-formulas thereof: Formula (I) or a pharmaceutically acceptable salt thereof, where each X independently is O or S, each Y independently is O or S, and each R1 independently is defined herein; and a liposome composition comprising the cationic lipid of formula I or a sub-formula thereof, and methods of delivering agents, such as nucleic acids including mRNA, in vivo, by administering to a subject the liposome comprising the cationic lipid of formula I or a sub-formula thereof, where the agent is encapsulated within the liposome.

  本发明提供了一种生物可降解的化合物，其化学式为I，以及其子式：化学式（I）或其药学上可接受的盐，其中每个X独立地为O或S，每个Y独立地为O或S，每个R1独立地在此处定义；以及包含化学式I或其子式的阳离子脂质的脂质体组合物，以及通过向主体给予包含化学式I或其子式的阳离子脂质的脂质体来递送药剂（例如核酸，包括mRNA）的方法，在此过程中，药剂被封装在脂质体内。
• BASE-MODIFIED RNA FOR INCREASING THE EXPRESSION OF A PROTEIN
  申请人：Hoerr Ingmar

  公开号：US20100047261A1

  公开（公告）日：2010-02-25

  The present application describes a base-modified RNA and the use thereof for increasing the expression of a protein and for the preparation of a pharmaceutical composition, especially a vaccine, for the treatment of tumours and cancer diseases, heart and circulatory diseases, infectious diseases, autoimmune diseases or monogenetic diseases, for example in gene therapy. The present invention further describes an in vitro transcription method, in vitro methods for increasing the expression of a protein using the base-modified RNA, and an in vivo method.

  本申请描述了一种基础修饰的RNA及其用于增加蛋白质表达和制备药物组合物的用途，特别是用于治疗肿瘤和癌症、心脏和循环系统疾病、传染病、自身免疫性疾病或单基因遗传病，例如基因治疗。本发明还描述了一种体外转录方法、使用基础修饰RNA增加蛋白质表达的体外方法以及一种体内方法。
• Aptamer-toxin molecules and methods for using same
  申请人：——

  公开号：US20040249130A1

  公开（公告）日：2004-12-09

  Materials and methods are provided to prepare therapeutic conjugates for the treatment of proliferative diseases. The therapeutic conjugates of the invention comprise a targeting moiety conjugated to a therapeutic moiety. The therapeutic moiety of the conjugates of the present invention have a cytotoxic effect and are useful in the treatment of proliferative diseases.

  提供了用于治疗增生性疾病的治疗结合物的材料和方法。本发明的治疗结合物包括与治疗物质结合的靶向基团。本发明的结合物的治疗物质具有细胞毒作用，并可用于治疗增生性疾病。
• Stabilized Aptamers to PSMA and Their Use as Prostate Cancer Therapeutics
  申请人：Diener John L.

  公开号：US20090105172A1

  公开（公告）日：2009-04-23

  The present invention provides stabilized, high affinity nucleic acid ligands to PSMA. Methods for the identification and preparation of novel, stable, high affinity ligands to PSMA using the SELEX™ method with 2′-O-methyl substituted nucleic acids, and cell surface SELEX™ are described herein. Also included are methods and compositions for the treatment and diagnosis of disease characterized by PSMA expression, using the described nucleic acid ligands.

  本发明提供了稳定的、高亲和力的核酸配体，用于与PSMA结合。本文描述了使用2'-O-甲基取代核酸的SELEX™方法和细胞表面SELEX™方法，鉴定和制备新的、稳定的、高亲和力的PSMA配体的方法。还包括使用所述核酸配体治疗和诊断PSMA表达疾病的方法和组合物。